Mark Gaze

Dr Mark Gaze has been a Consultant Clinical Oncologist at Great Ormond Street Hospital (GOSH) since 1993. He is also a consultant at University College Hospital, where radiotherapy for children from GOSH is delivered.

He is Chairman of the Children's Cancer and Leukaemia Group (www.cclg.org.uk). He is the lead for radiotherapy in clinical trials run by the European Paediatric Soft Tissue Sarcoma Group (EpSSG) and also for the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN).

He is committed to improving standards of care and has contributed to national guidance on good practice in Paediatric Radiotherapy and Molecular Radiotherapy. He is the author of many scientific papers, and books and book chapters in the field of cancer.

Specialisms

Dr Gaze's particular areas of expertise include the management of cancer in children and young people with radiotherapy and the use of molecular radiotherapy in adults and children.

Departments

Qualifications and training

Dr Gaze qualified from Saint Bartholomew's Hospital and undertook specialist cancer training in Edinburgh and Glasgow. His MD research was on the targeted radiotherapy of neuroblastoma, a subject in which he maintains a strong clinical interest.

He has a major interest in postgraduate medical education and was formerly a member of the Specialist Training Board of the Faculty of Clinical Oncology, Royal College of Radiologists, and Chairman of the Specialty Training Committee in Clinical Oncology London, Kent Surrey and Sussex and Eastern (Essex and Hertfordshire) Deaneries.

He contributes extensively to teaching and training and courses for continuing professional development. He was Co-Chair of the Local Organising Committee for the 44th International Society of Paediatric Oncology Congress held in London in October 2012.

Research interests

He is a member of the National Cancer Research Institute’s Children’s Cancer and Leukaemia Clinical Studies Group. His personal research is in the field of paediatric radiotherapy and molecular radiotherapy, especially for neuroblastoma and soft tissue sarcomas.

Contact

Tel: 020 3447 9088
Email: mark.gaze@uclh.nhs.uk